Dynamic convergence of autism disorder risk genes across neurodevelopment.
Meilin Fernandez GarciaKayla G Retallick-TownsleyApril PruittElizabeth DavidsonYi DaiSarah E FitzpatrickAnnabel SenSophie CohenOlivia LivotiSuha KhanGrace DossouJen CheungP J Michael DeansZuoheng WangLaura M HuckinsEllen HoffmanKristen J BrennandPublished in: bioRxiv : the preprint server for biology (2024)
Over a hundred risk genes underlie risk for autism spectrum disorder (ASD) but the extent to which they converge on shared downstream targets to increase ASD risk is unknown. To test the hypothesis that cellular context impacts the nature of convergence, here we apply a pooled CRISPR approach to target 29 ASD loss-of-function genes in human induced pluripotent stem cell (hiPSC)-derived neural progenitor cells, glutamatergic neurons, and GABAergic neurons. Two distinct approaches (gene-level and network-level analyses) demonstrate that convergence is greatest in mature glutamatergic neurons. Convergent effects are dynamic, varying in strength, composition, and biological role between cell types, increasing with functional similarity of the ASD genes examined, and driven by cell-type-specific gene co-expression patterns. Stratification of ASD genes yield targeted drug predictions capable of reversing gene-specific convergent signatures in human cells and ASD-related behaviors in zebrafish. Altogether, convergent networks downstream of ASD risk genes represent novel points of individualized therapeutic intervention.
Keyphrases
- autism spectrum disorder
- genome wide
- genome wide identification
- intellectual disability
- attention deficit hyperactivity disorder
- dna methylation
- stem cells
- genome wide analysis
- spinal cord
- bioinformatics analysis
- copy number
- endothelial cells
- clinical trial
- single cell
- high glucose
- binding protein
- study protocol
- long non coding rna
- placebo controlled
- double blind